CLIP4 Antibody

Basic Research Questions

• What is CLIP4 and what cellular functions is it involved in?

  CLIP4, also known as CAP-GLY domain-containing linker protein 4 or restin-like protein 2 (RSNL2), has emerged as a molecule with multiple cellular roles. Research indicates that CLIP4 is involved in:

  • Endoplasmic reticulum stress (ERS) response in hepatocellular carcinoma

  • Immune response and cell adhesion processes

  • Epithelial-mesenchymal transition (EMT) in cancer cells

  • Cell division and chromosome segregation

  Recent studies have revealed contradictory roles of CLIP4 in different cancer types. In hepatocellular carcinoma, it appears to be procarcinogenic , while in breast cancer, it demonstrates tumor suppressor characteristics with reduced expression correlating with poorer prognosis .

• Which applications are CLIP4 antibodies commonly used for?

  CLIP4 antibodies have been validated for multiple research applications, with different products showing varying application profiles:

  Application	Validated Products	Typical Dilutions
  Western Blot (WB)	Most commercial antibodies	1:500-1:3000
  ELISA	Many products	1:2000-1:40000
  Immunohistochemistry (IHC)	Select antibodies	1:20-1:100
  Immunocytochemistry (ICC)	Some products	1:100-1:500
  Immunofluorescence (IF)	Limited products	~4 μg/ml

  Method selection should be guided by your specific research question. For expression level studies, Western blot and IHC are preferred, while protein localization studies benefit from ICC/IF approaches .

• How do I choose between polyclonal and monoclonal CLIP4 antibodies?

  The choice between polyclonal and monoclonal antibodies depends on your experimental goals:

  Polyclonal CLIP4 antibodies:

  • Recognize multiple epitopes on the CLIP4 protein

  • Generally provide higher sensitivity for detection of low-abundance proteins

  • Useful when protein conformation may vary (denatured vs. native)

  • Examples include rabbit polyclonal antibodies targeting internal regions

  Monoclonal CLIP4 antibodies:

  • Target a single epitope with high specificity

  • Provide consistent lot-to-lot reproducibility

  • Superior for quantitative comparisons across experiments

  • Essential for therapeutic development research

  For initial characterization studies, polyclonal antibodies may offer broader detection capability, while monoclonal antibodies are preferable for quantitative longitudinal studies requiring consistent reagents .

• What are the recommended storage conditions for CLIP4 antibodies?

  Proper storage is crucial for maintaining antibody performance. Based on manufacturer recommendations:

  • Most CLIP4 antibodies should be stored at -20°C for up to one year

  • Many are supplied in a stabilizing buffer containing glycerol (typically 50%), allowing storage without freeze-thaw damage

  • Additional components often include PBS (pH 7.4), sodium azide (0.02%) as preservative, and sometimes BSA (0.5%)

  • Avoid repeated freeze-thaw cycles as this can lead to antibody degradation and diminished performance

  If working with the antibody regularly, consider aliquoting into smaller volumes before freezing to minimize freeze-thaw cycles. For short-term storage (1-2 weeks), most antibodies can be kept at 4°C .

Intermediate Research Questions

• What are the recommended protocols for using CLIP4 antibodies in Western blot?

  For optimal Western blot results with CLIP4 antibodies:

  Sample preparation:

  • Extract proteins using lysis buffers compatible with your sample type

  • For cell lines like HepG2 or Jurkat cells that express CLIP4, standard RIPA buffer is typically sufficient

  Gel electrophoresis and transfer:

  • Load appropriate amount of protein (20-50 μg per lane)

  • CLIP4 has a predicted band size of approximately 76 kDa

  Antibody incubation:

  • Block membrane in 5% non-fat milk or BSA in TBST

  • Dilute primary CLIP4 antibody according to manufacturer recommendations (typical range: 1:500-1:3000)

  • Incubate overnight at 4°C with gentle agitation

  • Wash thoroughly with TBST (3-5 times, 5-10 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody

  Detection:

  • Develop using enhanced chemiluminescence

  • Multiple sample types have been validated, including human liver tissue, tonsil tissue, and cell lines like RT4, U-251 MG

• How can I optimize immunohistochemistry staining with CLIP4 antibodies?

  For successful IHC staining of CLIP4:

  Tissue preparation:

  • Use formalin-fixed, paraffin-embedded tissues sectioned at 4-6 μm thickness

  • Mount sections on positively charged slides

  Antigen retrieval:

  • Perform heat-mediated antigen retrieval using citrate buffer (pH 6.0)

  • This step is critical as formalin fixation can mask epitopes

  Staining protocol:

  • Follow standard two-step immunohistochemistry procedures

  • For CLIP4 in liver cancer tissue microarrays, an effective protocol includes:

    • Primary antibody dilution of 1:100 for anti-CLIP4

    • Scoring system: Intensity (0-3) × Percentage of positive cells (0-4)

    • High expression defined as scores ≥6

  Controls:

  • Include positive controls (tissues known to express CLIP4)

  • Include negative controls (primary antibody omitted)

  • Consider using tissues with variable CLIP4 expression for comparison

• What controls should I include when using CLIP4 antibodies in my experiments?

  Proper controls are essential for result interpretation and troubleshooting:

  For Western blot:

  • Positive control: Lysates from cells known to express CLIP4 (e.g., HepG2, Jurkat)

  • Loading control: Probe for housekeeping proteins like β-actin or GAPDH

  • Negative control: Samples where CLIP4 is not expressed or has been knocked down

  For immunoprecipitation:

  • Input control: Whole lysate sample to verify presence of target protein

  • Isotype control: Matching IgG subclass antibody to assess non-specific binding

  • Bead-only control: Beads without antibody to detect non-specific binding to matrix

  For immunohistochemistry:

  • Tissue controls: Include known positive and negative tissues

  • Technical controls: Omit primary antibody to assess secondary antibody specificity

  Remember that controls should be processed identically to experimental samples to ensure valid comparisons .

• How do I validate CLIP4 antibody specificity in my experimental system?

  Antibody validation is crucial for ensuring reliable results:

  Genetic approaches:

  • Use CLIP4 knockdown or knockout models (e.g., siRNA-transfected cells)

  • The study in search result #1 demonstrated successful CLIP4 knockdown in Hep3B cells using siRNA with >70% efficiency

  Overexpression systems:

  • Express CLIP4 in cells with low endogenous levels (e.g., Huh7 cells)

  • Verify increased signal with CLIP4 antibody

  Multiple antibody approach:

  • Use antibodies targeting different CLIP4 epitopes (e.g., internal region vs. N-terminal)

  • Compare staining patterns across different applications

  Application-specific validation:

  • For Western blot: Observe band at expected molecular weight (76 kDa)

  • For IHC/ICC: Compare staining pattern with published literature

  • For IP: Verify pulled-down protein by Western blot

Advanced Research Questions

• How can I use CLIP4 antibodies to study protein-protein interactions through co-immunoprecipitation?

  Co-immunoprecipitation (co-IP) is valuable for investigating CLIP4's interaction partners:

  Experimental design:

  • Choose a lysis buffer that preserves protein complexes (typically non-ionic detergents like NP-40 or Triton X-100)

  • For CLIP4, which is involved in EMT and immune response pathways, consider using buffers with phosphatase inhibitors to preserve signaling interactions

  Immunoprecipitation procedure:

  • Pre-clear lysate with protein A/G beads to reduce non-specific binding

  • Incubate lysate with CLIP4 antibody at 4°C overnight with gentle rotation

  • Add protein A/G beads and incubate 1-4 hours

  • Wash thoroughly (3-5 times) with cold buffer

  • Elute protein complexes and analyze by Western blot

  Analysis of interacting partners:

  • Probe membranes with antibodies against suspected interaction partners

  • Consider mass spectrometry for unbiased identification of novel interactors

  • Based on CLIP4's functions, potential interacting partners might include proteins involved in ERS response, EMT, or immune signaling pathways

• What approaches can help resolve contradictory findings about CLIP4's role in different cancer types?

  Research shows that CLIP4 has apparently opposing roles in different cancers:

  Comprehensive expression analysis:

  • Analyze CLIP4 expression across multiple cancer types using public databases (TCGA, Oncomine)

  • Compare expression patterns in hepatocellular carcinoma (where it appears oncogenic) versus breast cancer (where it shows tumor suppressor properties)

  Functional genomics approaches:

  • Perform gain- and loss-of-function studies in multiple cell types

  • For example, in HCC cells, CLIP4 knockdown inhibited proliferation and colony formation, while overexpression promoted these phenotypes

  • Compare with breast cancer models where expression patterns differ

  Context-dependent signaling analysis:

  • Investigate upstream regulators in different tissues

  • Research has identified an ERS-RELA-miR-222-5p-CLIP4 transcriptional network in HCC

  • Examine if different signaling pathways regulate CLIP4 in other cancer types

  Tissue-specific interactome mapping:

  • Use co-IP and mass spectrometry to identify tissue-specific binding partners

  • Different protein interactions could explain varied functions across tissues

• How can I quantitatively assess CLIP4 expression in relation to immune cell infiltration in tumor tissues?

  Given CLIP4's association with immune response:

  Multiplex immunohistochemistry:

  • Perform multiplex IHC/IF to simultaneously visualize CLIP4 and immune cell markers

  • Use antibodies against markers for specific immune cell populations (e.g., ITGAM for neutrophils, STAT5A for Th2 cells, CSF1R for monocytes)

  Digital pathology analysis:

  • Employ whole slide imaging and quantitative image analysis

  • Measure CLIP4 expression levels and correlate with immune cell density

  • Analysis should include spatial relationships between CLIP4-expressing cells and immune cells

  Transcriptomic approaches:

  • Use techniques like spatial transcriptomics or single-cell RNA-seq

  • Correlate CLIP4 expression with immune cell signatures

  • In HCC, CLIP4 expression was positively correlated with various immune cells including macrophages, T helper cells, and neutrophils

  Bioinformatic tools:

  • Utilize algorithms like TIMER, CIBERSORT, or ssGSEA for immune cell proportion estimation

  • Apply these to datasets with CLIP4 expression data

  • This approach revealed significant correlations between CLIP4 expression and proportions of 24 immune cell subtypes in HCC

• What methodologies are recommended for multiplexed detection of CLIP4 alongside other proteins?

  For comprehensive protein profiling:

  Multiplex immunofluorescence:

  • Use spectrally distinct fluorophores for each target protein

  • Ensure antibodies are raised in different species to avoid cross-reactivity

  • Example: CLIP4 visualization in U-2 OS cells using fluorescent antibodies alongside nuclear probe and microtubule markers

  Sequential immunohistochemistry:

  • Apply, image, and strip/quench antibodies sequentially

  • This allows use of antibodies from the same species

  • Particularly useful for studying CLIP4 alongside its potential interactors

  Mass cytometry (CyTOF):

  • Label antibodies with rare earth metals instead of fluorophores

  • Enables simultaneous detection of >40 proteins

  • Useful for comprehensive profiling of CLIP4 in complex tissue environments

  In situ proximity ligation assay (PLA):

  • Detect protein-protein interactions with spatial resolution

  • Useful for confirming CLIP4 interactions identified in co-IP experiments

  • Particularly valuable for investigating the ERS-CLIP4 relationship in cancer tissues

• How do DNA methylation patterns affect CLIP4 expression and antibody detection in cancer research?

  DNA methylation is an important regulator of CLIP4:

  Methylation analysis approaches:

  • Use bisulfite sequencing or methylation-specific PCR to assess CLIP4 promoter methylation

  • CLIP4 has shown cancer-specific methylation patterns in colorectal cancer

  • The MethSurv platform can be used to analyze CLIP4 CpG methylation patterns and prognostic value

  Integrated methylation-expression analysis:

  • Correlate methylation status with protein levels detected by antibodies

  • In HCC, DNA methylation patterns of CLIP4 have significant prognostic value

  • This may explain variable antibody detection results across different tumor samples

  Experimental considerations:

  • Treatment with demethylating agents (e.g., 5-aza-dC) may restore CLIP4 expression

  • This can serve as a positive control for antibody specificity in hypermethylated samples

  • CLIP4, alongside C9orf50 and KCNQ5, has been identified as a promising epigenetic biomarker that can distinguish between plasma from colorectal cancer patients and healthy individuals

• What are the best approaches for studying the role of CLIP4 in endoplasmic reticulum stress response?

  Given CLIP4's involvement in ERS:

  ERS induction models:

  • Treat cells with ERS inducers (e.g., tunicamycin, thapsigargin)

  • Monitor CLIP4 expression changes using validated antibodies

  • Research shows that ERS significantly upregulates CLIP4 expression

  Co-localization studies:

  • Perform dual immunofluorescence for CLIP4 and ERS markers (e.g., GRP78)

  • Research has demonstrated correlation between CLIP4 and GRP78 expression in HCC tissues

  Functional assessment:

  • Manipulate CLIP4 expression and measure effects on ERS pathway components

  • Monitor changes in key ERS markers like GRP78, CHOP, and XBP1 splicing

  TF-miRNA-mRNA regulatory network analysis:

  • Investigate transcriptional and post-transcriptional regulation

  • Research has identified an ERS-RELA-miR-222-5p-CLIP4 transcriptional network

  • Use ChIP-seq, miRNA-seq, and RNA-seq for comprehensive analysis

• How should I design experiments to study the differential roles of CLIP4 isoforms?

  CLIP4 has multiple isoforms that may have distinct functions:

  Isoform identification:

  • Use antibodies targeting isoform-specific regions

  • Note that CLIP4 has at least 4 isoforms according to some sources

  Expression vector construction:

  • Generate constructs expressing specific CLIP4 isoforms

  • Ensure proper tagging for downstream detection and purification

  Isoform-specific knockdown:

  • Design siRNAs or shRNAs targeting unique regions of specific isoforms

  • Verify knockdown efficiency using isoform-specific primers

  Functional characterization:

  • Compare phenotypic effects of different isoforms

  • Assess proliferation, migration, and EMT marker expression

  • Research shows CLIP4 affects proliferation, migration, and EMT in HCC cells

  Interaction partner comparison:

  • Perform co-IP with tagged isoforms to identify shared and unique binding partners

  • Map interaction domains using truncation mutants